Pelitinib Completed Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) / Neoplasms, Lung Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00067548Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer